Literature DB >> 24874530

Orbital lymphoproliferative disorders (OLPDs): value of MR imaging for differentiating orbital lymphoma from benign OPLDs.

K Haradome1, H Haradome2, Y Usui1, S Ueda1, T C Kwee3, K Saito4, K Tokuuye4, J Matsubayashi5, T Nagao5, H Goto1.   

Abstract

BACKGROUND AND
PURPOSE: Accurate discrimination of orbital lymphoma from benign orbital lymphoproliferative disorders is crucial for treatment planning. We evaluated MR imaging including DWI and contrast-enhanced MR imaging for differentiating orbital lymphoma from benign orbital lymphoproliferative disorders.
MATERIALS AND METHODS: Forty-seven histopathologically proved orbital lymphoproliferative disorders (29 orbital lymphomas and 18 benign orbital lymphoproliferative disorders) were evaluated. Two board-certified radiologists reviewed visual features on T1-weighted, fat-suppressed T2-weighted, diffusion-weighted, and contrast-enhanced MR images. For quantitative evaluation, ADC and contrast-enhancement ratio of all lesions were measured and optimal cutoff thresholds and areas under curves for differentiating orbital lymphoma from benign orbital lymphoproliferative disorders were determined using receiver operative characteristic analysis; corresponding sensitivities and specificities were calculated.
RESULTS: Multivariate logistic regression analysis showed that ill-defined tumor margin (P = .003) had a significant association with orbital lymphoma whereas the "flow void sign" (P = .005) and radiologic evidence of sinusitis (P = .0002) were associated with benign orbital lymphoproliferative disorders. The mean ADC and contrast-enhancement ratio of orbital lymphomas were significantly lower than those of benign orbital lymphoproliferative disorders (P < .01). An ADC of less than 0.612 × 10(-3) mm(2)/s and a contrast-enhancement ratio of less than 1.88 yielded areas under curves of 0.980 and 0.770, sensitivity of 94.1% and 95.5%, and specificities of 93.3% and 80.0% for predicting orbital lymphoma, respectively.
CONCLUSIONS: Some characteristic MR imaging features and quantitative DWI and contrast-enhanced MR imaging are useful in further improving the accuracy of MR imaging for differentiation of orbital lymphoma from benign orbital lymphoproliferative disorders.
© 2014 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2014        PMID: 24874530      PMCID: PMC7966261          DOI: 10.3174/ajnr.A3986

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  23 in total

1.  Differentiation between benign and malignant orbital tumors at 3-T diffusion MR-imaging.

Authors:  Ahmed Abdel Khalek Abdel Razek; Sahar Elkhamary; Amani Mousa
Journal:  Neuroradiology       Date:  2011-02-01       Impact factor: 2.804

Review 2.  Orbital lymphoproliferative disorders.

Authors:  A Garner
Journal:  Br J Ophthalmol       Date:  1992-01       Impact factor: 4.638

3.  Assessment of lymph node metastases by contrast-enhanced MR imaging in a head and neck cancer model.

Authors:  Ki Chang Lee; Woo Kyung Moon; Jin Wook Chung; Seung Hong Choi; Nariya Cho; Joo Hee Cha; Eun Hye Lee; Sun Mi Kim; Hoe Suk Kim; Moon Hee Han; Kee Hyun Chang
Journal:  Korean J Radiol       Date:  2007 Jan-Feb       Impact factor: 3.500

4.  MR imaging of orbital inflammatory syndrome, orbital cellulitis, and orbital lymphoid lesions: the role of diffusion-weighted imaging.

Authors:  R Kapur; A R Sepahdari; M F Mafee; A M Putterman; V Aakalu; L J A Wendel; P Setabutr
Journal:  AJNR Am J Neuroradiol       Date:  2008-10-08       Impact factor: 3.825

5.  MRI patterns in orbital malignant lymphoma and atypical lymphocytic infiltrates.

Authors:  Gur Akansel; Lloyd Hendrix; Beth A Erickson; Ali Demirci; Anne Papke; Arzu Arslan; Ercument Ciftci
Journal:  Eur J Radiol       Date:  2005-02       Impact factor: 3.528

6.  Ocular adnexal lymphoma: diffusion-weighted mr imaging for differential diagnosis and therapeutic monitoring.

Authors:  Letterio S Politi; Reza Forghani; Claudia Godi; Antonio G Resti; Maurilio Ponzoni; Stefania Bianchi; Antonella Iadanza; Alessandro Ambrosi; Andrea Falini; Andrés J M Ferreri; Hugh D Curtin; Giuseppe Scotti
Journal:  Radiology       Date:  2010-08       Impact factor: 11.105

Review 7.  Imaging of orbital lymphoproliferative disorders.

Authors:  G E Valvassori; S S Sabnis; R F Mafee; M S Brown; A Putterman
Journal:  Radiol Clin North Am       Date:  1999-01       Impact factor: 2.303

8.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics.

Authors:  Alexander C Guo; Thomas J Cummings; Rajesh C Dash; James M Provenzale
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

9.  Orbital lymphoma: imaging features and differential diagnosis.

Authors:  Gema Priego; Carles Majos; Fina Climent; Amadeo Muntane
Journal:  Insights Imaging       Date:  2012-04-18

10.  Clinical Aspects of IgG4-Related Orbital Inflammation in a Case Series of Ocular Adnexal Lymphoproliferative Disorders.

Authors:  Masayuki Takahira; Yoshiaki Ozawa; Mitsuhiro Kawano; Yoh Zen; Shoko Hamaoka; Kazunori Yamada; Kazuhisa Sugiyama
Journal:  Int J Rheumatol       Date:  2012-04-02
View more
  15 in total

1.  MR-based radiomics signature in differentiating ocular adnexal lymphoma from idiopathic orbital inflammation.

Authors:  Jian Guo; Zhenyu Liu; Chen Shen; Zheng Li; Fei Yan; Jie Tian; Junfang Xian
Journal:  Eur Radiol       Date:  2018-04-09       Impact factor: 5.315

2.  Characteristics of orbital lymphoma: a clinicopathological study of 26 cases.

Authors:  Daniel Briscoe; Christine Safieh; Yokrat Ton; Hava Shapiro; Ehud I Assia; Dvora Kidron
Journal:  Int Ophthalmol       Date:  2017-03-31       Impact factor: 2.031

3.  Orbital malignant lesions in adults: multiparametric MR imaging.

Authors:  Bo Sun; Liyuan Song
Journal:  Jpn J Radiol       Date:  2017-05-26       Impact factor: 2.374

4.  A deep learning model combining multimodal radiomics, clinical and imaging features for differentiating ocular adnexal lymphoma from idiopathic orbital inflammation.

Authors:  Xiaoyang Xie; Lijuan Yang; Fengjun Zhao; Dong Wang; Hui Zhang; Xuelei He; Xin Cao; Huangjian Yi; Xiaowei He; Yuqing Hou
Journal:  Eur Radiol       Date:  2022-06-08       Impact factor: 7.034

5.  Intravoxel incoherent motion (IVIM) 3 T MRI for orbital lesion characterization.

Authors:  Augustin Lecler; Loïc Duron; Mathieu Zmuda; Kevin Zuber; Olivier Bergès; Marc Putterman; Julien Savatovsky; Laure Fournier
Journal:  Eur Radiol       Date:  2020-08-01       Impact factor: 5.315

6.  Advances in magnetic resonance imaging of orbital disease.

Authors:  Rebecca E Tanenbaum; Remy Lobo; Alon Kahana; Sara T Wester
Journal:  Can J Ophthalmol       Date:  2021-05-28       Impact factor: 2.592

7.  Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging.

Authors:  Bela S Purohit; Maria Isabel Vargas; Angeliki Ailianou; Laura Merlini; Pierre-Alexandre Poletti; Alexandra Platon; Bénédicte M Delattre; Olivier Rager; Karim Burkhardt; Minerva Becker
Journal:  Insights Imaging       Date:  2015-10-31

8.  Diffusion Weighted Imaging for Differentiating Benign from Malignant Orbital Tumors: Diagnostic Performance of the Apparent Diffusion Coefficient Based on Region of Interest Selection Method.

Authors:  Xiao-Quan Xu; Hao Hu; Guo-Yi Su; Hu Liu; Hai-Bin Shi; Fei-Yun Wu
Journal:  Korean J Radiol       Date:  2016-08-23       Impact factor: 3.500

9.  Differentiation of orbital lymphoma and idiopathic orbital inflammatory pseudotumor: combined diagnostic value of conventional MRI and histogram analysis of ADC maps.

Authors:  Jiliang Ren; Ying Yuan; Yingwei Wu; Xiaofeng Tao
Journal:  BMC Med Imaging       Date:  2018-05-02       Impact factor: 1.930

10.  Repeatability of apparent diffusion coefficient and intravoxel incoherent motion parameters at 3.0 Tesla in orbital lesions.

Authors:  Augustin Lecler; Julien Savatovsky; Daniel Balvay; Mathieu Zmuda; Jean-Claude Sadik; Olivier Galatoire; Frédérique Charbonneau; Olivier Bergès; Hervé Picard; Laure Fournier
Journal:  Eur Radiol       Date:  2017-07-04       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.